Company news

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) news

Harmony Biosciences Holdings, Inc. news releases on 6ix. Latest, Oct 1, 2026: Harmony Biosciences Announces Poster Presentation at the 17th European…

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) news

Press releases & updates

Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress

Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference

Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile

Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026

Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference

Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy

Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026

Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG

Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome

Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting

Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation

Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence

Harmony Biosciences to Participate in Upcoming Investor Conferences

Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M

Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance

Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome

Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress

Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference

Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025

Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025

Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series

Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025

Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation

Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​

Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome

Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference

Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands

Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs

Harmony Biosciences Provides Update on the Status of the Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia

Harmony Biosciences to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts

HARMONY BIOSCIENCES TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT

HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders

Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance